aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Locanabio is a gene therapy company focused on pioneering RNA-targeting therapies to treat devastating diseases. Their mission is to harness the power of RNA biology to develop transformative treatments. Locanabio's innovative approach aims to address a wide range of genetic disorders, providing new hope for patients with limited options.
Locanabio has made significant strides in the field of gene therapy, leveraging cutting-edge RNA-targeting technologies. Their work has the potential to revolutionize the treatment landscape for genetic diseases, offering more precise and effective solutions. The company's advancements have garnered attention from the scientific community and investors alike, positioning them as a leader in RNA-based therapies.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Gene Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Locanabio founded?
Locanabio was founded in 2016.
Where is Locanabio's headquarters located?
Locanabio's headquarters is located in San Diego, CA, US.
When was Locanabio's last funding round?
Locanabio's most recent funding round was for $100M (USD) in December 2020.
How many employees does Locanabio have?
Locanabio has 175 employees as of Feb 4, 2024.
How much has Locanabio raised to-date?
As of July 05, 2023, Locanabio has raised a total of $155.6M (USD) since Dec 14, 2020.
Add Comparison
Total Raised to Date
$155.6M
USD
Last Update Dec 14, 2020
Last Deal Details
$100M
USD
Dec 14, 2020
Series B
Total Employees Over Time
175
As of Feb 2024
Locanabio Address
3545 John Hopkins Court
suite 200
San Diego,
California
92121
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts